A Phase 1/2A, Dose Escalation, Randomized, Placebo Controlled Study of the Safety, Feasibility, and Efficacy of Subcutaneous Plasminogen (Human) 10 for the Treatment of Chronic Tympanic Membrane Perforation

Trial Profile

A Phase 1/2A, Dose Escalation, Randomized, Placebo Controlled Study of the Safety, Feasibility, and Efficacy of Subcutaneous Plasminogen (Human) 10 for the Treatment of Chronic Tympanic Membrane Perforation

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 28 Mar 2018

At a glance

  • Drugs Plasminogen (Primary)
  • Indications Ear disorders
  • Focus Adverse reactions
  • Sponsors ProMetic Life Sciences
  • Most Recent Events

    • 28 Mar 2018 According to a ProMetic Life Sciences media release, the study is being conducted at a single center in Sweden, under the supervision of Cecilia Engmer Berglin, MD, PhD from the Department of Otorhinolaryngology at Karolinska University Hospital in Stockholm, Sweden.
    • 20 Feb 2018 According to a ProMetic Life Sciences media release, interim clinical data readouts are expected later this year.
    • 24 Nov 2017 Status changed from planning to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top